HSPB1 and ovarian carcinoma: In conclusion, our study demonstrates that cisplatin-resistant ovarian cancer cell lines upregulate HSP27 and FAO to deplete cisplatin-induced ROS to attenuate the cytotoxic effect of cisplatin.